ArticleAnnals of surgical oncology2026
Long-Term Clinical and Functional Outcomes after Intercalary Allograft Reconstruction for Oncologic Indications.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntercalary allograft after resection of bone tumors is associated with low failure rates. However, literature on the long-term outcomes of this technique is limited, and long-term functional outcomes remain unknown. This study sought to assess allograft survival, risk factors for failure, and functional outcomes for patients with a minimum 10-year follow-up period.
methodsThis study retrospectively identified patients treated with intercalary allograft of the femur or tibia for oncologic indications. Allograft failure was assessed using the Henderson classification for biologic reconstruction. Early, midterm, and late failures were defined as those occurring before 2 years, between 2 and 10 years, and after 10 years of follow-up evaluation, respectively.
resultsOf the 64 patients in the study, 29 had a femur allograft and 35 had a tibia allograft. The median follow-up period was 22 years. Complications developed in 34 patients (53%), with 79% having multiple complications. Non-union failures (type 2) comprised 42% of the early failures and 43% of the midterm failures, whereas structural failures (type 3) represented 100% of the late failures. The risk factors for allograft failure were neoadjuvant radiotherapy and chemotherapy. The median TESS-LE and LEFS scores were 97.3% and 76.3% for the patients with femur allografts and 98.3% and 86.3% for those with tibia allografts, respectively. The PROMIS Pain Interference and Physical Function scores were 51.2 and 45.2 for the patients with femur allografts and 40.7 and 50 for those with tibia allografts, respectively.
conclusionNon-union and structural failures were the most common causes of early and late failure, respectively. Although complications occurred frequently, the long-term functional outcomes for femur and tibia intercalary allografts were good.
Indexed as
Identifiers
41331172What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.